AlphAIAlphAI — Financial news for AI agents
benzinga.comOCT 142 min read$LQDA

Liquidia Shares Surge 42.48% After Hours - United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA)

Liquidia (LQDA) shares rose 42.48% after hours to $38.20 following a settlement with United Therapeutics (UTHR). The deal resolves litigation after a court ruled UTHR's patents were infringed. LQDA will pay $175M immediately, $145.4M in 2027, and $60.3M this month. YUTREPIA sales and cash will fund payments, with Q3 sales at $222.7M and $396.1M in cash.

Original reporting
benzinga.com
Published Oct 14, 2026, 5:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 5:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$LQDA
Bullish
high confidence
Mentioned
$LQDA · $UTHR
Relevance
8/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$LQDABullishHigh
01

Why it matters

The settlement clears legal hurdles, provides Liquidia with cash flow expectations, and removes uncertainty for United Therapeutics.

02

Market read

The news triggered a sharp after‑hours price jump for Liquidia and resolves a legal risk for both firms.

03

What to watch

Potential future royalty or licensing arrangements not disclosed.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Liquidia and United Therapeutics resolved a patent infringement dispute over the inhaled drug YUTREPIA.

Company-level read

Ticker impact

$LQDABullishHigh confidence
Context

Liquidia announced a $175M settlement with United Therapeutics, causing its shares to surge 42.48% after hours.

Expected impact

likely continued upward pressure as market digests the settlement and cash inflow expectations

Evidence & confidence

The settlement resolves litigation and includes sizable cash payments, which the market viewed as a catalyst.

$UTHRNeutralMedium confidence
Context

United Therapeutics is the counterparty in the $175M settlement with Liquidia, ending pending litigation.

Expected impact

minimal immediate impact; market may view the resolution as neutral to slightly positive

Evidence & confidence

The deal resolves a patent dispute but does not involve cash outflow for United Therapeutics.

Market effects

Sector

The settlement may ease litigation risk perception in the biotech/pharma sector.

Regional

Limited to U.S. biotech stocks.

Global

Low; primarily affects the two companies involved.

Counterpoint

What could challenge this read

Some investors may view the settlement payment as a cash drain for Liquidia despite the share rally.

Key entities

  • Company
    Liquidia Corporation

    Biopharmaceutical company settling litigation with United Therapeutics.

  • Company
    United Therapeutics Corporation

    Patent holder in the settlement with Liquidia.

Read at source← All news

StoryLiquidia settles all litigation with United Therapeutics

Also covered by

3 outlets

Related articles

OCT 14
$UTHRMed

Jefferies raises United Therapeutics stock price target on settlement

Jefferies raised its price target for United Therapeutics (UTHR) to $728 from $704, citing a settlement with Liquidia Technologies. The settlement includes a $380.7M payment to UTHR, resolving litigation and preserving its exclusivity in a pulmonary hypertension indication. UTHR's Q2 2026 earnings beat estimates, but revenue fell short. Analysts have mixed views on the stock's valuation.

investing.com2 min
OCT 14
$LQDAHighAI 8/10

Why is Liquidia stock surging today?

Liquidia Corporation (LQDA) stock surged 46.7% in pre-market trading after announcing a $380.7M settlement with United Therapeutics, resolving all ongoing lawsuits. The deal removes legal risks and ensures YUTREPIA's market presence, funded by sales and cash reserves. Short interest and company-specific developments drove the rally.

investing.com2 min
OCT 14
$LQDAHighAI 8/10

Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics

Liquidia (LQDA) stock rose 47% in pre-market trading after announcing a $380.7M settlement with United Therapeutics (UTHR), resolving all ongoing lawsuits. The deal includes payments to UTHR and removes a PH-ILD indication from Liquidia's Yutrepia drug. Liquidia expects to fund the settlement through Yutrepia sales and existing cash, with Q3 2026 sales reported at $227.1M.

tipranks.com2 min